Business Trends– category –
-
Beam Therapeutics Secures FDA IND Clearance for Liver-Targeted LNP Formulation BEAM-304 as PKU Treatment, Phase 1/2 Trial Imminent
Business Wire / Nasdaq USA Overview Beam Therapeutics announced FDA Investigational New Drug (IND) clearance for BEAM-304, its lead candidate for Phenylketonuria (PKU). BEAM-304 is a liver-targeted lipid nanoparticle (LNP) formulated bas... -
Italian DeepTech X-nano Raises €3.7M for Methane-to-Graphite Pilot Plant
Startupbusiness イタリア Overview Italian DeepTech startup X-nano, an IIT spin-off, has secured €3.7 million in seed funding to establish a pilot plant for its non-catalytic methane pyrolysis technology. This investment aims to accelerat... -
Canon Invests ¥50 Billion in New NIL Factory in Japan, Targets 2nm Process to Challenge ASML’s EUV Dominance
Move Silicon Japan Overview Canon is investing ¥50 billion (approximately $320 million USD) in a new lithography equipment factory in Utsunomiya, Japan, to aggressively advance its Nanoimprint Lithography (NIL) technology. The company cl... -
HydroGraph Launches Fractal Graphene Paste to Seamlessly Integrate Graphene into Existing Industrial Products like Cement and Coatings
YouTube (KE Report) USA Overview HydroGraph has introduced a new fractal graphene paste product designed to simplify the integration of graphene into existing industrial products. This user-friendly paste allows for easy incorporation in... -
Orca Bio Expands East Coast Manufacturing Capacity and Triples West Coast Workforce Ahead of Potential Orca-T® Commercial Launch, with FDA PDUFA Date Set for July 6, 2026
Business Wire USA Overview Orca Bio announced significant manufacturing expansions for its investigational cell therapy, Orca-T®, in anticipation of its commercial launch. This includes establishing new East Coast manufacturing capacity ... -
SonoThera Raises $125M Series B to Advance Safer Ultrasound-Mediated Gene Therapies for Duchenne Muscular Dystrophy and ADPKD into Clinical Development
BioSpace USA Overview SonoThera has secured $125 million in Series B financing to advance its gene therapy programs for Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into clinical development.... -
Cell Therapy Weekly: uniQure Plans BLA Submission for Huntington’s Gene Therapy AMT-130; Ernexa Prepares IND for iMSC, Autolus Reports Early Phase I Data for SLE CAR-T
Cell & Gene Therapy Insights USA Overview uniQure plans to submit a Biologics License Application (BLA) for AMT-130, a gene therapy for Huntington's disease, in Q3 2026, based on three-year Phase I/II data. Ernexa Therapeutics has comple... -
Portal Biotechnologies Raises $9M to Expand Cell Engineering Platform, Attracting Merck & Co. and AbbVie
FirstWord HealthTech USA Overview Portal Biotechnologies secured $9 million to advance its cell engineering platform, which has drawn partnerships with Merck & Co. and AbbVie. The platform leverages mechanoporation for efficient intr... -
Cellares Secures $327M in Series D Funding, Including ARK Invest, and Expands Major Manufacturing Agreements with Bristol Myers Squibb and Cabaletta Bio
AllSci USA Overview Cellares has extended its Series D financing to $327 million with a new $50 million investment, specifically aimed at scaling cell therapy manufacturing. As an Integrated Development and Manufacturing Organization (ID... -
Pharmaceutical and Biotech M&A Surges in 2026, Driven by Pipeline Reinforcement and Expansion into Emerging Therapeutic Areas
DistilINFO Publications USA Overview The pharmaceutical and biotechnology sectors are experiencing a significant surge in M&A activity in 2026, as major drugmakers actively seek to fortify their pipelines and expand into novel therap...
